The Food and Drug Administration asked to review Pfizer’s data on two doses now, while the company continues to assess whether three doses would be more effective.The Food and Drug Administration asked to review Pfizer’s data on two doses now, while the company continues to assess whether three doses would be more effective.Coronavirus (2019-nCoV), Vaccination and Immunization, Food and Drug Administration, Pfizer Inc, Children and Childhood, Coronavirus Omicron Variant, Clinical Trials, Centers for Disease Control and PreventionRead More
